Are Analysts Bullish about MEI Pharma, Inc. (NASDAQ:MEIP) after last week?

February 15, 2018 - By Henry Gaston

 Are Analysts Bullish about MEI Pharma, Inc. (NASDAQ:MEIP) after last week?

MEI Pharma, Inc. (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Wednesday, May 31. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. The rating was maintained by Oppenheimer on Wednesday, August 2 with “Buy”. Stifel Nicolaus maintained MEI Pharma, Inc. (NASDAQ:MEIP) rating on Wednesday, September 6. Stifel Nicolaus has “Hold” rating and $2.5 target. The company was maintained on Friday, September 4 by Wedbush. The company was maintained on Wednesday, June 14 by Oppenheimer. Below is a list of MEI Pharma, Inc. (NASDAQ:MEIP) latest ratings and price target changes.

06/09/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $2.5 Maintain

The stock decreased 0.46% or $0.01 during the last trading session, reaching $2.16. About 20,324 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 20.90% since February 15, 2017 and is uptrending. It has outperformed by 4.20% the S&P500.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $80.03 million. The companyÂ’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

More notable recent MEI Pharma, Inc. (NASDAQ:MEIP) news were published by: Prnewswire.com which released: “MEI Pharma Announces FDA Clearance of Investigational New Drug Application for …” on January 08, 2018, also Prnewswire.com with their article: “MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer” published on April 03, 2017, Marketwatch.com published: “MEI Pharma Inc.” on August 08, 2016. More interesting news about MEI Pharma, Inc. (NASDAQ:MEIP) were released by: Seekingalpha.com and their article: “MEI Pharma: A Prime 2018 Turn Around Candidate” published on November 24, 2017 as well as Streetinsider.com‘s news article titled: “MEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical …” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.